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Letters to the Editor
Figure 1. Immunohistochemistry of normal human corneas 
probed with antibody against α‐synuclein. Sections were stained 
with FITC resulting in a green fluorescence. Note that α‐
synuclein is expressed in corneal epithelium and endothelium 
but not in stroma. The magnification is ×400.
Identification and Localization of Alpha‐Synuclein 
in Human Cornea
Dear Editor
Alpha‐synuclein is a widespread neuronal presynaptic 
protein found predominantly in the central nervous system, 
and it is an element of the neuropathological features of 
several neurodegenerative disorders including the dementia 
with Lewy bodies and the Parkinson’s disease. At the extra‐
neural tissue, the normal distribution and functions of α‐
synuclein remain especially elusive. Though there was one 
report that described the absence of α‐synuclein in human 
cornea using the Western blots, we had access to data from 
immunohistochemical staining with fluorescence indicating 
high immunoreactivity of α‐synuclein in human corneal 
epithelium and endothelium. Our results are consistent with 
the expression of α‐synuclein in the normal human cornea. 
The presence of α‐synuclein in normal human cornea 
suggests that this molecule is widely distributed and functions 
in mammalian extra‐neural tissue.
Samin Hong, MD, Hyung Keun Lee, MD, PhD, 
Chan Yun Kim, MD, PhD, Gong Je Seong, MD, PhD.
Institute of Vision Research, Department of Ophthalmology, 
Yonsei University College of Medicine, Seoul, Korea
Synucleins are small proteins (112‐140 amino acids) that 
are transported axonally after their synthesis in the cell body. 
Alpha‐synuclein, a member of synuclein family, is a 
widespread neuronal presynaptic protein found predominantly 
in the central nervous system and with lower expression in 
other tissues.1‐3 It has been implicated specifically in several 
neurodegenerative diseases, and it is an element of the 
neuropathological features of several neurodegenerative 
disorders including the dementia with Lewy bodies and the 
Parkinson’s disease.4‐7 It is largely accepted that intraneural 
aggregates of α‐synuclein are neurotoxic, though there are 
some evidences that they may have some protective role.8‐10
Even though there are considerable informations pointing 
to the role of α‐synuclein in the different human diseases, its 
normal distributions and functions especially at the extra‐
neural tissue remain elusive. In the ocular tissue, Surguchov 
et al.3 reported the presence of α‐synuclein in the human 
retina and optic nerve. Recently, we had access to data from 
immunohistochemical staining with fluorescence indicating 
high immunoreactivity of α‐synuclein in the human corneal 
epithelium and endothelium. As such, we were surprised by the 
study of Surguchov et al.3 who reported the absence of α‐
synuclein in the human corneal tissue using the Western blots.
We used immunohistochemical staining with fluorescence 
to confirm that the α‐synuclein was indeed expressed in the 
human cornea. We certify that all applicable institutional and 
governmental regulations concerning the ethical use of human 
tissues were followed during this research. And all procedures 
followed the guidelines of the declaration of Helsinki.
Three normal human eyeballs (age 36 to 50 years) donated 
for keratoplasty were used. After removal of corneal buttons 
for keratoplasty, the remained tissue containing the peripheral 
cornea was fixed with 4% p‐formaldehyde and subsequently 
embedded in paraffin. Each specimen was serially sectioned 
into 4‐µm sections and mounted on glass slides. After serial 
paraffin sections were deparaffinized in xylenes and 
rehydrated with a graded concentration of ethanol, 
immunohistochemical staining was performed using the ABC 
Elite system (Vector Laboratories, Burlinghame, CA) 
according to the manufacturer's instructions. Briefly, the 
sections were incubated with horse serum for 30 minutes. 
After several washing steps, the sections were incubated with 
the mouse monoclonal IgG (1:500 dilution) specific for 
human α‐synuclein (Santa Cruz Biotech, Santa Cruz, CA) for 
12 hr at 4°C. Binding of the primary antibody was detected 
with fluorescein isothiocyanate (FITC)‐conjugated goat anti‐
mouse IgG (1:200 dilution, Sigma, St. Louis, MO) after 
1 hour of incubation at room temperature. The slides were 
examined with a fluorescent microscope.
All three of the donors had normal eyes without any ocular 
Kor J Ophthalmol Vol.22, No.2, 2008
146
pathology, and they had no history nor family history of any 
neurodegenerative diseases. In order to investigate the 
expression of α‐synuclein in normal cornea, we probed three 
corneal tissues with the antibody against α‐synuclein. The 
staining of the specimens was demonstrated with fluorescent 
microscopy. Alpha‐synuclein was highly expressed in corneal 
epithelium and endothelium (Fig. 1). However, it was not 
stained in corneal stroma. Under identical conditions, no 
fluorescence was obtained with sections not exposed to the 
primary antibody and solely incubated with the FITC‐
conjugated secondary antibody.
Our results are consistent with the expression of α‐
synuclein in the normal human cornea. We cannot account 
for the discrepancy between our results and those of 
Surguchov et al.3 However, we suspect that their method of 
Western blotting of the whole corneal lysate may have 
resulted in a less sensitive detection.
Even though we could not explain the exact role of the α‐
synuclein in normal human cornea, the presence of α‐synuclein 
in normal human cornea suggests that this molecule is widely 
distributed and functions in mammalian extra‐neural tissue.
* This work was supported by the Students' Association of the 
Graduate School of Yonsei University and funded by the 
Graduate School of Yonsei University.
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